MGN
MCID: MMB011
MIFTS: 58

Membranous Nephropathy (MGN)

Categories: Nephrological diseases, Rare diseases

Aliases & Classifications for Membranous Nephropathy

MalaCards integrated aliases for Membranous Nephropathy:

Name: Membranous Nephropathy 57 12 53 29 15
Membranous Glomerulonephritis 12 53 15 73
Idiopathic Membranous Glomerulonephritis 59 6 73
Membranous Nephropathy, Susceptibility to 57 13
Idiopathic Membranous Nephropathy 53 55
Glomerulonephritis, Membranous 53 44
Extramembranous Glomerulonephritis 53
Nephropathy Membranous 55
Membranous Gn 53
Mbnp 57
Mgn 53

Classifications:

Orphanet: 59  
Rare renal diseases


External Ids:

OMIM 57 614692
Disease Ontology 12 DOID:10976
ICD10 33 N03.2
MeSH 44 D015433
NCIt 50 C34645
SNOMED-CT 68 77182004
Orphanet 59 ORPHA97560
ICD10 via Orphanet 34 N04.2
UMLS via Orphanet 74 C0086445

Summaries for Membranous Nephropathy

OMIM : 57 Membranous nephropathy, a major cause of the nephrotic syndrome in adults, is characterized by the presence of glomerular deposits that typically contain immunoglobulin and complement components. Two major antigens, both of which are membrane glycoproteins, have been identified in human membranous nephropathy. Neutral endopeptidase (MME; 120520) is the alloantigen involved in membranous nephropathy in neonates whose mothers have a deficiency of this enzyme. The second is the M-type phospholipase A2 receptor (PLA2R1; 604939), the first antigen identified in adults with idiopathic membranous nephropathy, which is generally considered to be an autoimmune disease. In addition, autoantibodies against aldose reductase (AKR1B1; 103880), mitochondrial superoxide dismutase-2 (SOD2; 147460), and THSD7A (612249) have been found in serum and glomeruli from patients with idiopathic membranous nephropathy. Familial occurrence has been noted by Short et al. (1984) and Bockenhauer et al. (2008) (summary by Stanescu et al., 2011 and Tomas et al., 2014). (614692)

MalaCards based summary : Membranous Nephropathy, also known as membranous glomerulonephritis, is related to nephrotic syndrome and kidney disease. An important gene associated with Membranous Nephropathy is MME (Membrane Metalloendopeptidase), and among its related pathways/superpathways are NF-kappaB Signaling and Tuberculosis. The drugs Angiotensin II and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include kidney, b cells and bone, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

NIH Rare Diseases : 53 Membranous nephropathy is a kidney disease characterized by inflammation of the structures inside the kidney that help filter wastes and fluids. When the glomerular basement membrane becomes thickened, it does not work normally, allowing large amounts of protein to be lost in the urine. Symptoms develop gradually and may include swelling, fatigue, weight gain, and high blood pressure. In many cases, the underlying cause of membranous nephropathy is not known. Some cases are associated with other conditions (lupus), infections (hepatitis B and C), cancer or as a side effect of certain medications. The goal of treatment is to reduce symptoms and slow the progression of the disease. 

Wikipedia : 76 Membranous glomerulonephritis (MGN) is a slowly progressive disease of the kidney affecting mostly... more...

Related Diseases for Membranous Nephropathy

Diseases in the Membranous Nephropathy family:

Congenital Membranous Nephropathy Due to Maternal Anti-Neutral Endopeptidase Alloimmunization

Diseases related to Membranous Nephropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 319)
# Related Disease Score Top Affiliating Genes
1 nephrotic syndrome 30.8 ALB B2M CD2AP NPHS1 NPHS2
2 kidney disease 30.7 ACE ALB B2M C3 CD2AP NPHS1
3 interstitial nephritis 30.6 ACE ALB TINAG
4 glomerulonephritis 30.5 ALB C3 CD79A LRP2 NPHS1 NPHS2
5 focal segmental glomerulosclerosis 30.5 ACE ALB CD2AP NPHS1 NPHS2
6 iga glomerulonephritis 30.2 ACE ALB CD79A NPHS1 NPHS2 SERPINB7
7 membranoproliferative glomerulonephritis 30.1 ALB C3 CD79A NPHS1
8 microvascular complications of diabetes 3 30.1 ACE ALB NPHS1
9 myeloma, multiple 30.0 ALB B2M MME TNF
10 systemic lupus erythematosus 29.9 ACE ALB C3 CD79A HLA-DQA1 TNF
11 celiac disease 1 29.8 ALB CD79A HLA-DQA1 TNF
12 viral hepatitis 29.8 ALB HLA-DQA1 TNF
13 chronic graft versus host disease 29.7 ALB CD79A TNF
14 lipoid nephrosis 29.7 ALB CD2AP CD79A NPHS1 NPHS2 SERPINB7
15 guillain-barre syndrome 29.7 ALB CD79A TNF
16 chronic kidney failure 29.7 ACE ALB B2M NPHS1 NPHS2
17 peritonitis 29.7 ALB B2M TNF
18 diabetes mellitus, insulin-dependent 29.6 ACE ALB B2M HLA-DQA1
19 alport syndrome and thin basement membrane nephropathy 12.3
20 congenital membranous nephropathy due to maternal anti-neutral endopeptidase alloimmunization 12.2
21 hematuria, benign familial 12.0
22 hepatitis 10.5
23 hepatitis b 10.5
24 sporadic idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 10.3 CD2AP NPHS2
25 loeffler syndrome 10.3 ACE ALB
26 alport syndrome, x-linked 10.3
27 focal segmental glomerulosclerosis 1 10.3
28 uveoparotid fever 10.2 ACE TNF
29 kidney hypertrophy 10.2 ALB NPHS1 NPHS2
30 atrial septal defect 3 10.2 CD2AP NPHS1 NPHS2
31 familial idiopathic steroid-resistant nephrotic syndrome with focal segmental hyalinosis 10.2 CD2AP NPHS1 NPHS2
32 familial nephrotic syndrome 10.2 CD2AP NPHS1 NPHS2
33 nephrotic syndrome, type 1 10.2 CD2AP NPHS1 NPHS2
34 beryllium disease 10.2 HLA-DQA1 TNF
35 denys-drash syndrome 10.2 CD2AP NPHS1 NPHS2
36 subacute cutaneous lupus erythematosus 10.2 ACE TNF
37 nephrotic syndrome, type 6 10.2 NPHS1 NPHS2
38 skin sarcoidosis 10.2 ACE TNF
39 nephrosclerosis 10.2 ACE NPHS1 NPHS2
40 frasier syndrome 10.2 CD2AP NPHS1 NPHS2
41 obstructive nephropathy 10.2 ACE ALB TINAG
42 granulomatous dermatitis 10.2 ACE TNF
43 rheumatic heart disease 10.2 ACE HLA-DQA1 TNF
44 pyelonephritis 10.2 ACE ALB TNF
45 crescentic glomerulonephritis 10.2
46 immunodeficiency 43 10.2 ALB B2M
47 arteries, anomalies of 10.2 ACE ALB TNF
48 root caries 10.2 ALB CD79A
49 glucose metabolism disease 10.2 ACE ALB TNF
50 acquired metabolic disease 10.1 ACE ALB TNF

Graphical network of the top 20 diseases related to Membranous Nephropathy:



Diseases related to Membranous Nephropathy

Symptoms & Phenotypes for Membranous Nephropathy

Clinical features from OMIM:

614692

MGI Mouse Phenotypes related to Membranous Nephropathy:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.1 ACE ALB B2M C3 CD2AP CD79A
2 endocrine/exocrine gland MP:0005379 10.02 ACE ALB B2M C3 CD2AP HLA-DQA1
3 hematopoietic system MP:0005397 10.02 ACE B2M C3 CD2AP CD79A HLA-DQA1
4 immune system MP:0005387 9.9 ACE B2M C3 CD2AP CD79A HLA-DQA1
5 liver/biliary system MP:0005370 9.56 ACE ALB B2M C3 CD79A MME
6 renal/urinary system MP:0005367 9.32 ACE ALB C3 CD2AP CD79A LRP2

Drugs & Therapeutics for Membranous Nephropathy

Drugs for Membranous Nephropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 132)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Angiotensin II Approved, Investigational Phase 4,Phase 3,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
2
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
3
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
4
Tacrolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 104987-11-3 445643 439492
5
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
6
Entecavir Approved, Investigational Phase 4,Not Applicable 142217-69-4 153941
7 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
9 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
10 Angiotensin Receptor Antagonists Phase 4,Phase 3,Not Applicable
11 Angiotensin II Type 1 Receptor Blockers Phase 4,Not Applicable
12 Antihypertensive Agents Phase 4,Not Applicable
13 Angiotensinogen Phase 4,Phase 3,Not Applicable
14 Neurotransmitter Agents Phase 4,Phase 3
15 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
17 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Antitubercular Agents Phase 4,Phase 3,Phase 2
19 Cyclosporins Phase 4,Phase 3,Phase 2
20 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
21 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Antifungal Agents Phase 4,Phase 3,Phase 2
24 Dermatologic Agents Phase 4,Phase 3,Phase 2
25 Calcineurin Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
26 beta-endorphin Phase 4,Phase 2,Phase 1
27 Adrenocorticotropic Hormone Phase 4,Phase 2,Phase 1
28 Melanocyte-Stimulating Hormones Phase 4,Phase 2,Phase 1
29 Tripterygium Phase 4,Not Applicable
30 Immunoglobulin A Phase 4,Phase 2,Not Applicable
31 Antiviral Agents Phase 4,Phase 1,Phase 2,Not Applicable
32 Endorphins Phase 4
33
rituximab Approved Phase 3,Phase 2,Early Phase 1 174722-31-7 10201696
34
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
35
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
36 Deflazacort Approved, Investigational Phase 3 14484-47-0
37
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Not Applicable 302-25-0
38
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Not Applicable 2921-57-5
39
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 3,Not Applicable 6055-19-2, 50-18-0 2907
40
Prednisone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Not Applicable 53-03-2 5865
41
Chlorambucil Approved Phase 3 305-03-3 2708
42
Serine Approved, Nutraceutical Phase 3 56-45-1 5951
43
Prednisolone hemisuccinate Experimental Phase 3,Phase 2,Not Applicable 2920-86-7
44 Lipid Regulating Agents Phase 3
45 Vasoconstrictor Agents Phase 3
46 diuretics Phase 3
47 Diuretics, Potassium Sparing Phase 3
48 Serine Proteinase Inhibitors Phase 3
49 Pharmaceutical Solutions Phase 3,Phase 2,Phase 1
50 Mineralocorticoids Phase 3

Interventional clinical trials:

(show top 50) (show all 69)
# Name Status NCT ID Phase Drugs
1 Acthar for Treatment of Proteinuria in Membranous Nephropathy Patients Completed NCT01386554 Phase 4 Repository Corticotropin Injection;Placebo
2 To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) Completed NCT00518219 Phase 4 TW
3 Treatment of Resistant Nephrotic Syndrome With ACTH Gel (ACTHAR) Completed NCT01129284 Phase 4 ACTHAR gel
4 Adrenocorticotropic Hormone in Membranous Nephropathy Recruiting NCT03025828 Phase 4 ACTHar
5 Mycophenolate Mofetil Plus Steroid in the Treatment Of Patients With Progressive Idiopathic Membranous Nephropathy Recruiting NCT03170323 Phase 4 Mycophenolate Mofetil;Cyclosporins
6 Tacrolimus Combined With Entecavir on HBV Associated Glomerulonephritis(HBV-GN) Recruiting NCT03062813 Phase 4 Tacrolimus &entecavir;placebo & entecavir
7 Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (IMG) Active, not recruiting NCT00843856 Phase 4 tacrolimus;tacrolimus and mycophenolate mofetil
8 Acthar for Treatment of Post-transplant FSGS Not yet recruiting NCT02399462 Phase 4 Acthar
9 Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Terminated NCT01129557 Phase 4 Aliskiren;Valsartan
10 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Withdrawn NCT01926054 Phase 4 Acthar gel
11 Evaluate Rituximab Treatment for Idiopathic Membranous Nephropathy Unknown status NCT01508468 Phase 3 symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin);experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
12 Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy Unknown status NCT01282073 Phase 3 Mycophenolate mofetil, low dose steroid;Cyclosporin, low dose steroid
13 Rituximab in Membranous Nephropathy Completed NCT00425217 Phase 2, Phase 3 Rituximab
14 Mycophenolate Mofetil in Membranous Nephropathy Completed NCT00135967 Phase 2, Phase 3 mycophenolate mofetil orally 1000 mg twice a day (BID);prednisone 0,5 mg/kg orally on alternate days;intravenous (i.v.) methylprednisolone 1000 mg, total 9
15 Treatment of Patients With Idiopathic Membranous Nephropathy Completed NCT00135954 Phase 3 Cyclophosphamide and steroids
16 Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental Completed NCT00404833 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and chlorambucil
17 Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome Completed NCT00362531 Phase 2, Phase 3 tacrolimus combined with prednisone
18 A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis Completed NCT00404794 Phase 3 prednisolone and mycophenolate mofetil;prednisolone and tacrolimus
19 Rituximab Versus Steroids and Cyclophosphamide in the Treatment of Idiopathic Membranous Nephropathy Recruiting NCT03018535 Phase 3 Rituximab;Methylprednisolone;Cyclophosphamide
20 Sequential Therapy With Tacrolimus and Rituximab in Primary Membranous Nephropathy Active, not recruiting NCT01955187 Phase 3 TACROLIMUS;RITUXIMAB;METHYLPREDNISOLONE;CYCLOPHOSPHAMIDE
21 MEmbranous Nephropathy Trial Of Rituximab Active, not recruiting NCT01180036 Phase 2, Phase 3 Rituximab;Cyclosporine
22 Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment Active, not recruiting NCT02077868 Phase 3 MGN1703 treatment
23 A Controlled Study of Steroids Plus Cyclosporin Therapy for Patients of Idiopathic Membranous Nephropathy Unknown status NCT02173106 Phase 2 steroid & Cyclosporin
24 Treatment With Synthetic ACTH in High Risk Patients With Membranous Nephropathy Completed NCT00694863 Phase 2 tetracosactide hexacetaat
25 Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC Completed NCT02200081 Phase 2 MGN1703
26 Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy Completed NCT00050713 Phase 2 Sirolimus
27 Efficacy Study of a Maintenance Therapy With Immunomodulator MGN1703 in Patients With Advanced Colorectal Carcinoma Completed NCT01208194 Phase 2 MGN1703;Placebo
28 A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy Completed NCT01093157 Phase 1, Phase 2 Adrenocorticotrophic hormone ACTH
29 A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET) Completed NCT01265368 Phase 1, Phase 2
30 Toll-like Receptor 9 Agonist Treatment in Chronic HIV-1 Infection Completed NCT02443935 Phase 1, Phase 2 MGN1703;MGN1703
31 Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV Completed NCT02690103 Phase 2 pegylated IFN;Ribavirin
32 A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy Completed NCT01610492 Phase 2 belimumab
33 Peptide GAM Immunoadsorption Therapy in Autoimmune Membranous Nephropathy Recruiting NCT03255447 Phase 2
34 Safety and Efficacy of Filgotinib and GS-9876 in Adults With Lupus Membranous Nephropathy (LMN) Recruiting NCT03285711 Phase 2 Filgotinib;GS-9876;Filgotinib placebo;GS-9876 placebo
35 Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy Recruiting NCT00977977 Phase 2 Rituximab Infusion;Oral Cyclosporine
36 Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721 Recruiting NCT02682407 Phase 2
37 Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies Recruiting NCT03453619 Phase 2 APL-2
38 Personalized Medicine for Membranous Nephropathy Not yet recruiting NCT03804359 Phase 2 Rituximab
39 Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy Withdrawn NCT01762852 Phase 2 Belimumab 10 mg;Placebo
40 A Phase I Study to Assess Cardiac and General Safety and Pharmacokinetics of 60 mg MGN1703 Completed NCT01982747 Phase 1 MGN-Placebo;Placebo-MGN
41 Dose-Finding Pilot Study of ACTH in Patients With Idiopathic Membranous Nephropathy Completed NCT00805753 Phase 1 ACTH
42 A Phase 1 Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ManNAc in Subjects With Primary Podocyte Diseases Completed NCT02639260 Phase 1 N-acetyl-mannosamine (ManNAc)
43 Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies Recruiting NCT02668770 Phase 1 MGN1703;Ipilimumab
44 Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus Terminated NCT00479622 Phase 1 TRU-015
45 Clinical Study of QingReMoShen Granule to Treat Idiopathic Membranous Nephropathy Unknown status NCT01845688 Not Applicable Losartan Tablets & QingReMoShen Granule;Losartan Tablets & Placebo Granule
46 Study on Single-nucleotide-polymorphism in Idiopathic Membranous Nephropathy Unknown status NCT01799460 The Comprehensive Treatment Regimen of Traditional Chinese Medicine;The immunosuppressive agents
47 Phospholipase A2 Receptor (PLA2R1) Autoantibodies in Membranous Nephropathy in Kidney Transplantation Unknown status NCT01897961 Not Applicable
48 Study on the Therapeutic Effect of TCM Treatment for MDR MN Unknown status NCT02610595 Not Applicable Jianpixiaozhong particles and Wuse Dietotherapy
49 The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy Completed NCT00983034 Not Applicable lansoprazole, amoxicillin, clarithromycin
50 Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid Completed NCT01161459 Not Applicable Tripterygium wilfordii;FK506

Search NIH Clinical Center for Membranous Nephropathy

Cochrane evidence based reviews: glomerulonephritis, membranous

Genetic Tests for Membranous Nephropathy

Genetic tests related to Membranous Nephropathy:

# Genetic test Affiliating Genes
1 Membranous Nephropathy 29

Anatomical Context for Membranous Nephropathy

MalaCards organs/tissues related to Membranous Nephropathy:

41
Kidney, B Cells, Bone, Skin, Liver, Neutrophil, Lung

Publications for Membranous Nephropathy

Articles related to Membranous Nephropathy:

(show top 50) (show all 1128)
# Title Authors Year
1
Unmet challenges in membranous nephropathy. ( 30451735 )
2019
2
The Unpredictability of Idiopathic Membranous Nephropathy: An Illustrative Case Report. ( 29928646 )
2018
3
Anti-PLA2R antibody in a secondary cause of membranous nephropathy. ( 29250915 )
2018
4
Recurrent membranous nephropathy and acute cellular rejection in a patient treated with direct anti-HCV therapy (ledipasvir/sofosbuvir). ( 29968947 )
2018
5
Urine anti-PLA2R antibody is a novel biomarker of idiopathic membranous nephropathy. ( 29416596 )
2018
6
Membranous Nephropathy: Approaches to Treatment. ( 29852477 )
2018
7
A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up. ( 29924035 )
2018
8
Clinicopathological study of de novo membranous nephropathy of 'stage 0' after kidney transplantation. ( 29968407 )
2018
9
Membranous nephropathy associated with pregnancy: an anti-phospholipase A2 receptor antibody-positive case report. ( 29349731 )
2018
10
The clinicopathological features of patients with membranous nephropathy. ( 29403303 )
2018
11
A Cohort Study of Incidences and Risk Factors for Thromboembolic Events in Patients with Idiopathic Membranous Nephropathy. ( 29976278 )
2018
12
Liddle's-like syndrome associated with nephrotic syndrome secondary to membranous nephropathy: the first case report. ( 29792170 )
2018
13
Management of Membranous Nephropathy in the PLA<sub>2</sub>R Era. ( 29378770 )
2018
14
Primary membranous nephropathy presenting with crescentic glomerulonephritis 25 years after initial presentation: A case reporta8c. ( 29932409 )
2018
15
High urinary interleukin-8 levels is associated with poor prognosis in idiopathic membranous nephropathy. ( 29415357 )
2018
16
Acquired von Willebrand Syndrome Complicating Nephrotic Syndrome: A Case of a Patient With Membranous Nephropathy. ( 29568223 )
2018
17
Concurrent Presentation of Thrombotic Thrombocytopenic Purpura and Membranous Nephropathy. ( 29725652 )
2018
18
Correlation and discrepancy of phospholipase A2 receptor staining in membranous nephropathy in paraffin-embedded kidney biopsies. ( 29970727 )
2018
19
Anti-phospholipase A2 receptor antibodies in primary membranous nephropathy-10 key points. ( 29401359 )
2018
20
Concurrent isolated IgG2-positive membranous nephropathy and malignant B-cell lymphoma. ( 29766466 )
2018
21
Mannose-Binding Lectin2 Gene Polymorphism and IgG4 in Membranous Nephropathy. ( 29439276 )
2018
22
Rituximab-induced serum sickness in the treatment of idiopathic membranous nephropathy. ( 29423201 )
2018
23
Temporal Association Between PLA2R Antibodies and Clinical Outcomes in Primary Membranous Nephropathy. ( 29340324 )
2018
24
Urine proteomics of primary membranous nephropathy using nanoscale liquid chromatography tandem mass spectrometry analysis. ( 29445323 )
2018
25
Anti-neutrophil cytoplasmic antibody-associated glomerulonephritis with detection of myeloperoxidase and phospholipase A<sub>2</sub> receptor in membranous nephropathy-lesions: report of two patients with microscopic polyangiitis. ( 29792176 )
2018
26
Human anti-thrombospondin type 1 domain-containing 7A antibodies induce membranous nephropathy through activation of lectin complement pathway. ( 29769410 )
2018
27
Expression of phospholipase A2 receptor and IgG4 in patients with membranous nephropathy. ( 29881283 )
2018
28
Combined membranous nephropathy and tubulointerstitial nephritis as a rare renal manifestation of IgG4-related disease: a case-based literature review. ( 29388171 )
2018
29
Idiopathic membranous nephropathy in patients with diabetes mellitus: a diagnostic and therapeutic quandary! ( 29423200 )
2018
30
Diagnostic Test Accuracy of Serum Anti-PLA2R Autoantibodies and Glomerular PLA2R Antigen for Diagnosing Idiopathic Membranous Nephropathy: An Updated Meta-Analysis. ( 29755981 )
2018
31
Membranous Nephropathy in a Patient With Common Variable Immune Deficiency. ( 29854983 )
2018
32
Hemizygous Fabry disease associated with membranous nephropathy: A rare case reporta8c. ( 29792392 )
2018
33
The Effect of Mycophenolate Mofetil versus Cyclosporine as Combination Therapy with Low Dose Corticosteroids in High-risk Patients with Idiopathic Membranous Nephropathy: a Multicenter Randomized Trial. ( 29441742 )
2018
34
The prognostic value of phospholipase A2 receptor autoantibodies on spontaneous remission for patients with idiopathic membranous nephropathy: A meta-analysis. ( 29879066 )
2018
35
BAFF and APRIL expression as an autoimmune signature of membranous nephropathy. ( 29423047 )
2018
36
Segmental membranous nephropathy with severe IgG3 deposition. ( 29744961 )
2018
37
The skin-kidney connection: bullous pemphigoid associated with acute allograft rejection and membranous nephropathy. ( 29445491 )
2018
38
Membranous Nephropathy in a Patient with Charcot-Marie-Tooth Disease: Association of Myelin Mutations. ( 30271005 )
2018
39
Chronic Inflammatory Demyelinating Polyneuropathy With Concurrent Membranous Nephropathy: An Anti-paranode and Podocyte Protein Antibody Study and Literature Survey. ( 30538665 )
2018
40
CIDP, myasthenia gravis, and membranous glomerulonephritis - three autoimmune disorders in one patient: a case report. ( 30107838 )
2018
41
Network analysis of membranous glomerulonephritis based on metabolomics data. ( 30221719 )
2018
42
Membranous glomerulonephritis - a common, unspecific pattern of glomerular injury. ( 30509047 )
2018
43
Intravenous immunoglobulins modify relapsing membranous glomerulonephritis after kidney transplantation: a case report. ( 28805142 )
2018
44
Therapeutic Effect of a Novel Nano-Drug Delivery System on Membranous Glomerulonephritis Rat Model Induced by Cationic Bovine Serum. ( 29725902 )
2018
45
Polyarteritis Nodosa and Membranous Glomerulonephritis: Two Simultaneous Extrahepatic Manifestations of Hepatitis B. ( 29965852 )
2018
46
Comprehensive identification of immune-associated biomarkers based on network and mRNA expression patterns in membranous glomerulonephritis. ( 30041664 )
2018
47
Identification of a two-SNP PLA2R1 Haplotype and HLA-DRB1 Alleles as Primary Risk Associations in Idiopathic Membranous Nephropathy. ( 30349113 )
2018
48
MALDI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy. ( 30358918 )
2018
49
Membranous nephropathy followed by anti-glomerular basement disease: A case report and review of clinical presentation and treatment. ( 30364512 )
2018
50
Association between the HLA-DQA1 rs2187668 polymorphism and risk of idiopathic membranous nephropathy: A PRISMA-compliant meta-analysis. ( 30383665 )
2018

Variations for Membranous Nephropathy

ClinVar genetic disease variations for Membranous Nephropathy:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 MME NM_000902.3(MME): c.1342C> T (p.Arg448Ter) single nucleotide variant Pathogenic rs149905705 GRCh38 Chromosome 3, 155144383: 155144383
2 MME NM_000902.3(MME): c.1342C> T (p.Arg448Ter) single nucleotide variant Pathogenic rs149905705 GRCh37 Chromosome 3, 154862172: 154862172

Expression for Membranous Nephropathy

Search GEO for disease gene expression data for Membranous Nephropathy.

Pathways for Membranous Nephropathy

GO Terms for Membranous Nephropathy

Cellular components related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 9.83 ACE B2M C3 CD2AP CD79A HLA-DQA1
2 membrane raft GO:0045121 9.73 CD79A NPHS2 PECAM1 TNF
3 external side of plasma membrane GO:0009897 9.63 ACE B2M CD79A LRP2 PECAM1 TNF
4 endosome lumen GO:0031904 9.46 LRP2 LRPAP1
5 slit diaphragm GO:0036057 9.4 NPHS1 NPHS2
6 extracellular exosome GO:0070062 9.36 ACE ALB B2M C3 CD2AP LRP2
7 rough endoplasmic reticulum lumen GO:0048237 9.26 LRPAP1 VTN
8 extracellular space GO:0005615 10.02 ACE ALB B2M C3 PECAM1 SERPINB7
9 extracellular region GO:0005576 10.02 ACE ALB B2M C3 LRPAP1 PLA2R1

Biological processes related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.63 B2M C3 HLA-DQA1 TINAG TNF VTN
2 amyloid-beta metabolic process GO:0050435 9.43 ACE MME
3 positive regulation of protein binding GO:0032092 9.43 ACE B2M VTN
4 replicative senescence GO:0090399 9.4 MME PLA2R1
5 amyloid-beta clearance GO:0097242 9.37 C3 MME
6 angiotensin maturation GO:0002003 9.32 ACE MME
7 receptor-mediated endocytosis GO:0006898 9.02 ALB LRP2 PLA2R1 TINAG VTN
8 regulation of receptor-mediated endocytosis GO:0048259 8.96 CD2AP LRPAP1

Molecular functions related to Membranous Nephropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 polysaccharide binding GO:0030247 9.16 TINAG VTN
2 drug binding GO:0008144 9.13 ACE ALB LRP2
3 exopeptidase activity GO:0008238 8.62 ACE MME

Sources for Membranous Nephropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....